Pharmaceutical

Biopharma firm Zetagen raises $9.79m in Series B financing round

Zetagen Therapeutics raised $9.79m in a Series B funding round to develop treatments for metastatic cancers to bone and soft tissue organs.

Aug 14, 2023 - 20:00
Biopharma firm Zetagen raises $9.79m in Series B financing round
Zetagen Therapeutics raised $9.79m in a Series B funding round to develop treatments for metastatic cancers to bone and soft tissue organs.
Read the original article

Tags:

Previous Article

ImPact enters partnership for pathologic myopia therapy development

Next Article

vTv announces Phase III plans for type 1 diabetes drug cadisegliatin

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Shareholders elect director’s romantic partner to Biogen’s board

STAT+: Shareholders elect director’s romantic partner t...

Jun 26, 2023

Polio cases derived from new oral vaccine reported for first time

Polio cases derived from new oral vaccine reported for ...

Mar 19, 2023

AZD-2389 by AstraZeneca for Metabolic Dysfunction-Assoc...

Jul 6, 2024